Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer

Published:2021-12 Issue: Volume: Page:
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Loibl Sibylle,Furlanetto Jenny^ORCID

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference77 articles.

1. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat Rev Drug Discov,2015

2. Cdks, cyclins and CKIs: roles beyond cell cycle regulation;Lim;Development,2013

3. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle;Matsushime;Cell,1991

4. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4;Kato;Genes Dev,1993

5. Cellular mechanisms of tumour suppression by the retinoblastoma gene;Burkhart;Nat Rev Cancer,2008

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

2. Combined targeted therapy with PI3K and CDK4/6, or FGFR inhibitors show synergistic effects in a neuroblastoma spheroid culture model;Biomedicine & Pharmacotherapy;2024-08

3. A Canadian real world prospective observational study assessing the impact of hormone therapy ± targeted therapy in the treatment of HR+ HER2- advanced breast cancer;2024-07-23

4. From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases;Frontiers in Immunology;2024-04-23

5. Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?;Clinical Breast Cancer;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3